{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seeds",
"mechanism": "Proteolytic cleavage at Asp-421 by caspase-2/3 produces aggregation-competent tau C-terminal fragments that are detected in human AD brain but absent in age-matched cognitively normal controls.",
"target_gene": "CASP2/CASP3",
"confidence_score": 0.75,
"novelty_score": 0.55,
"feasibility_score": 0.65,
"impact_score": 0.85,
"composite_score": 0.73,
"testable_prediction": "Caspase-2 knockout or selective inhibition in P301S mice will reduce D421 fragment accumulation and slow neurofibrillary tangle formation by >50%.",
"skeptic_concern": "Caspases have pleiotropic substrates; systemic inhibition may cause off-target toxicity, and the relationship between truncation and downstream aggregation kinetics remains unresolved."
},
{
"rank": 2,
"title": "p300/CBP-dependent K280 acetylation nucleates pathogenic tau conformers",
"mechanism": "Acetylation at Lys-280 within the microtubule-binding repeat domain converts tau into an aggregation-competent state by simultaneously disrupting microtubule binding and creating a β-sheet nucleation interface that templates unmodified tau.",
"target_gene": "EP300",
"confidence_score": 0.60,
"novelty_score": 0.75,
"feasibility_score": 0.50,
"impact_score": 0.80,
"composite_score": 0.67,
"testable_prediction": "Atomic-resolution cryo-EM of acetylated tau K280-repeat domain will reveal structural basis for nucleation, enabling rational design of allosteric p300 inhibitors.",
"skeptic_concern": "Current mechanistic claims exceed available structural evidence; correlation between K280 acetylation and disease does not establish causation without atomic-level conformational data."
},
{
"rank": 3,
"title": "Combinatorial PTM signatures distinguish pathological from physiological tau states",
"mechanism": "A quantitative threshold of phosphorylation (S396/S404), acetylation (K280), and truncation (D421) defines a pathological tau PTM signature that predicts therapeutic vulnerability better than any single modification alone.",
"target_gene": "MAPT",
"confidence_score": 0.55,
"novelty_score": 0.70,
"feasibility_score": 0.40,
"impact_score": 0.75,
"composite_score": 0.61,
"testable_prediction": "Multiplexed PTM mapping of individual tau molecules from AD vs. control brain using single-molecule fluorescence will quantify co-occurrence frequencies and identify dominant pathological combinations.",
"skeptic_concern": "Combinatorial targeting faces stoichiometry challenges; simultaneously modulating multiple PTMs pharmacologically is technically complex and may require multi-target drug cocktails."
}
],
"consensus_points": [
"Disease-specific PTMs (D421 truncation, K280 acetylation) show restricted expression patterns compared to phosphorylation, which is abundant in both physiological and pathological states.",
"Enzymatic modifications (acetylation by p300/CBP, proteolysis by caspases) are inherently more tractable therapeutic targets than non-enzymatic modifications like phosphorylation.",
"Structural evidence at atomic resolution is essential to establish causal mechanisms for any tau PTM-based intervention."
],
"dissent_points": [
"Theorist prioritized K280 acetylation as primary pathogenic driver based on disease correlation, while Expert assessed D421 truncation as highest translational priority given its enzymatic accessibility and cleaner disease specificity.",
"Skeptic challenged the sufficiency of any single-PTM hypothesis, arguing that tau pathology likely requires combinatorial PTM signatures rather than a unitary initiating modification."
],
"debate_summary": "The debate converged on disease-specific tau PTMs (D421 truncation, K280 acetylation) as more actionable targets than ubiquitous phosphorylation, with D421 truncation emerging as the top-ranked hypothesis due to its enzymatic amenability and demonstrated absence in healthy aging controls. K280 acetylation ranks second but requires additional structural validation to establish causation versus correlation; the combinational PTM signature hypothesis remains speculative but addresses the acknowledged complexity of multi-site PTM cross-talk in tau pathology."
}